Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. - Wikidata - awgldk - TriplyDB

Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure.

Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure.

http://www.wikidata.org/entity/Q42689974

about

Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies [Medication treatment of rheumatoid arthritis with a history of malignancy. Epidemiological data].Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.Clinicopathological correlations of podoplanin (gp38) expression in rheumatoid synovium and its potential contribution to fibroblast platelet crosstalk.Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study.Interleukin 6 and rheumatoid arthritis Role of IL-6 in Mycobacterium avium--associated immune reconstitution inflammatory syndrome.Tocilizumab in the treatment of rheumatoid arthritis and beyond.Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis.Pharmacogenomics of biological treatment in rheumatoid arthritis.Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.Adverse reactions to biologic agents and their medical management.A new alternative therapy in dermatology: tocilizumab.The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy.Safety profile of biological therapies for treating rheumatoid arthritis.Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy.Prodromal signs and symptoms of serious infections with tocilizumab treatment for rheumatoid arthritis: Text mining of the Japanese postmarketing adverse event-reporting database.Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.Pharmacologic Treatment of Noninfectious Uveitis.Clinical characteristics of adverse events associated with therapeutic monoclonal antibodies in Korea.Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy.A cytokine signal inhibitor for rheumatoid arthritis enhances cancer metastasis via depletion of NK cells in an experimental lung metastasis mouse model of colon cancer.Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE.Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).Tocilizumab: A Review in Rheumatoid Arthritis.Ten-year incidences of self-reported non-vertebral fractures in Japanese patients with rheumatoid arthritis: discrepancy between disease activity control and the incidence of non-vertebral fracture.Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs.Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting.Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA.Tocilizumab (Actemra).A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases.New insights and long-term safety of tocilizumab in rheumatoid arthritis

P2860

Q26746659-2E666929-CC6A-4E59-BED2-DF9CBB903237 Q26824970-DAF04A5F-99F2-4AD8-89AB-DDA3D0316276 Q26991673-2B453FD5-749E-4D98-90AA-8A7CBCB6FAEA Q31036951-758A774B-1CE1-42EA-AEF8-C8EEE0B31723 Q31151183-CC8F755D-BC45-46A3-A7F7-F93C637DA28B Q33763542-D0CB29B4-1C02-425A-B1F1-3564CE0E8CBD Q34770459-470E21A2-D2AB-4168-A4DC-D8AA7F12D0E7 Q35258244-E67E0B9F-7524-4C9C-81B2-406978601879 Q37453033-118E4454-C142-47C6-B02C-F7072AF424CC Q37553940-C0D31FA1-9A24-499B-BCC2-D115513C0F27 Q37626335-12225874-6AA3-4651-BC05-567FAFEA10D3 Q37682799-CCF7D809-A5CE-4260-A461-307D502BABB4 Q38164315-4F274916-A1DD-4175-8834-7D76BFE8CA0D Q38167894-203C5BAD-E0C1-4F7B-AC30-BAF7C42B9386 Q38200927-028FB94B-70D6-4F4D-B89A-C049CB05FB0A Q38238948-750F6B88-5FE0-4AD8-91F9-DC12C1BCF564 Q38507301-5BF02288-F19D-43B3-946E-C15BAA94D51C Q38648460-92D0E896-AC06-46E7-A138-A80EA4BE3278 Q38665700-188D8AC2-1C68-445C-9727-33BA2D89E506 Q38745066-34642A04-F71C-44C6-9225-0289772FF997 Q39110166-61A9A35A-AE10-4B89-9186-048E176A72F4 Q40062836-535475B2-1BD1-4871-8B59-C387342DD319 Q40169531-79DC7ECA-ABB9-41D2-9D7C-24D716263859 Q40450258-223B7D99-3612-4184-B5D8-2A33B2054959 Q40471375-3A35BB16-9763-455B-9122-45C923511978 Q40710011-196E3785-B818-4500-8BCA-5DE957EE42C0 Q41612628-13CCC6BE-41D0-4CC8-87AF-27C227317ADF Q41928628-91ACAAB0-6C89-48BD-A72E-786A97F1DC48 Q42698900-6FB7E24C-3285-4280-B45B-83F551DFDF9D Q43280791-D560E8BA-B491-4E92-8A37-A8BEEF209BC8 Q45150201-6070AA32-5653-4CDA-A40F-3FA9A14BECFC Q46172380-341DA8FA-64B0-4B99-8FD1-CA9ADD77EFA1 Q47292924-50A8FEF0-9474-45F9-95E5-F836A1BCC4ED Q47861250-E1E35EB0-7B10-4864-991D-6DE3D5578899 Q47978774-597DD16C-C178-4702-B945-0D2CBD2AA853 Q52675492-70962DA1-D701-4494-8753-733AC98E85B9 Q57482184-50855C35-C98C-4F9C-9042-0777C5DBE9E1

P2860

Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure.

http://www.wikidata.org/entity/Q42689974

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Longterm safety and efficacy o ...... f up to 4.6 years of exposure.

@en

Longterm safety and efficacy o ...... f up to 4.6 years of exposure.

@nl

type

label

Longterm safety and efficacy o ...... f up to 4.6 years of exposure.

@en

Longterm safety and efficacy o ...... f up to 4.6 years of exposure.

@nl

prefLabel

Longterm safety and efficacy o ...... f up to 4.6 years of exposure.

@en

Longterm safety and efficacy o ...... f up to 4.6 years of exposure.

@nl

P1433

Q42689974-AF8AC997-04D2-4713-BEC1-C060C55E166D

P1476

Q42689974-0CE85C67-B28F-468E-90A4-1F7F1E52D038

P2093

Q42689974-1AE17A82-CE7D-4AE0-9D58-7C306F067E96

Q42689974-1C1A62F1-E03F-403C-B29D-8D157F4976CF

Q42689974-2B8D8CA8-8EE5-4F58-B343-CCC5F8C0266F

Q42689974-517D5241-A89F-44D1-B159-E11A0074410F

Q42689974-688EF6CE-8BB8-47D4-B682-7B22104115D1

Q42689974-72ABABA5-15E1-49F2-9421-1106DB13DBC3

Q42689974-8C0B9D61-D1F2-4CFA-A32B-4409E0A4DEE4

Q42689974-92E22F09-9591-4837-A813-2AB8AD2A7889

Q42689974-DEBB1AA1-42DF-41C6-B32C-7239BE69F52B

P304

Q42689974-7A93B8FF-78CC-493A-B9EF-A9DF2C43F3F4

P31

Q42689974-9A986C53-F4A5-4B64-81F3-68B0E476FF00

P356

Q42689974-F7C94555-639E-4DAD-AD51-A2BD83B19ADA

P407

Q42689974-1D218B75-D8CF-4DAB-8877-45B15CDFF5AA

P433

Q42689974-D881FA47-4441-4149-9F52-1A7E03B60047

P478

Q42689974-AC75F2B0-5DF5-426C-9BB5-95D5AF1D0D50

P50

Q42689974-1A64BD27-5F1A-4F60-9EF7-4EAAA975F5E3

Q42689974-D45BCB4B-0B3A-4199-892C-19385FCC75B2

P577

Q42689974-A05CBBAA-7027-4C5D-9122-BDBCF4FF5066

P698

Q42689974-24F66E85-E298-4210-957D-158EB40AE9F3

P356

P1433

The Journal of Rheumatology

P1476

Longterm safety and efficacy o ...... f up to 4.6 years of exposure.

@en

P2093

Andrea Rubbert-Roth

http://www.w3.org/2001/XMLSchema#string

Anthony Sebba

http://www.w3.org/2001/XMLSchema#string

Joel Kremer

http://www.w3.org/2001/XMLSchema#string

Juan Gómez-Reino

http://www.w3.org/2001/XMLSchema#string

Majed Khraishi

http://www.w3.org/2001/XMLSchema#string

Mark C Genovese

http://www.w3.org/2001/XMLSchema#string

Robert Pilson

http://www.w3.org/2001/XMLSchema#string

Ronald Van Vollenhoven

http://www.w3.org/2001/XMLSchema#string

Sarah Williams

http://www.w3.org/2001/XMLSchema#string

P304

768-780

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3899/JRHEUM.120687

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P50

Andrea Rubbert-Roth

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23457383

http://www.w3.org/2001/XMLSchema#string